Table 3a. Therapeutic Management of Nonhospitalized Children With COVID-19
Last Updated: August 8, 2022
|Risk of Severe COVID-19||Panel's Recommendations|
|Aged 12–17 years||Aged <12 years|
|Symptomatic, Regardless of Risk Factors|
|Rating of Recommendations: A = Strong; B = Moderate; C = Weak|
Rating of Evidence: I = One or more randomized trials without major limitations; IIa = Other randomized trials or subgroup analyses of randomized trials; IIb = Nonrandomized trials or observational cohort studies; III = Expert opinion
a Molnupiravir is not authorized by the FDA for use in children aged <18 years and should not be used.
b See Table 3b for the Panel’s framework for assessing the risk of progression to severe COVID-19 based on patient conditions and COVID-19 vaccination status.
c Initiate treatment as soon as possible after symptom onset.
d Bebtelovimab is the only anti-SARS-CoV-2 mAb active against the current dominant circulating Omicron subvariants. In nonhospitalized adults, bebtelovimab may be used as an alternative therapy when none of the preferred therapies (i.e., ritonavir-boosted nirmatrelvir, remdesivir) are available, feasible to use, or clinically appropriate.
e The relative risk of severe COVID-19 for intermediate-risk patients is lower than the risk for high-risk patients but higher than the risk for low-risk patients.
f Low-risk patients include those with comorbid conditions that have a weak or unknown association with severe COVID-19. Patients with no comorbidities are included in this group.
Key: FDA = Food and Drug Administration; mAb = monoclonal antibody; the Panel = the COVID-19 Treatment Guidelines Panel